ehealth radio network
Episodes
Thursday Sep 28, 2023
Thursday Sep 28, 2023
Dr. Jose E Vidal who is currently the CEO of CytoImmune Therapeutics, a company at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials joins eHealth Radio and the Health News and Cancer Information Channels.
Listen to interview with host Eric Michaels and guest Dr. Jose E. Vidal discuss the following:
What is gene and cell therapy and how does it work?
What conditions can be treated with cell therapy?
What is the difference between treatment therapy and curative therapy?
What is the difference between chemo/radio therapy and immunotherapy for cancer?
When will cell therapy be available to patients? What are the limitations?
In conclusion, cell therapy is the next significant step in fighting hard to treat cancer and autoimmune conditions. It has been proven to provide results superior to any treatment seen before. Now, we are working on improving access for patients by optimizing the manufacturing process and lowering therapy cost.
Dr. Jose Eduardo Vidal obtained his doctoral degree in Cellular and Molecular Biology from the University of Puerto Rico. He started his career in the pharmaceutical industry in Wyeth as a process development scientist working with small molecules and the first Biologics development pipeline upon the acquisition of Immunex.
With Wyeth he worked on the development and commercial launch of Mylotarg (very first ADC). He continued to develop as a biopharmaceutical professional occupying positions of increased responsibility in Tech Services, Process Development and Quality. After 10 years with the company and managing 14 sites world wide Jose joined Amgen as the head of Process Development. With Amgen Jose managed the biologics new product development with over one hundred programs in the pipeline. Jose also managed the drug substance manufacturing organization as the VP of operations and also lead the global late stage product pipeline as the global VP of Process Development where he got acquainted with Cell and Gene therapy.
In 2018 Jose joined Atara where he led the company as SVP of Process Development and Global Quality to develop and submit for commercial licensing the first ever Allogeneic TCell therapy product (Ebvallo) which was approved for commercial distribution in Dec 2022. He also successfully designed and led the development of TCell therapy manufacturing process in stirred tank, perfusion bioreactors.
Lately Jose joined Cytoimmune Therapeutics as the Chief Operations Officer and has been working in starting up the company and the operation from the ground up with operations in PR. Cytoimmune is focused in developing oncology and autoimmune malignancies therapies based on Allogeneic NK-CAR cells.
Jose has also worked with other operations and startups as Pfizer and Biovail and has served as advisor for multiple biotechnology startups with 25 years in the industry in which he has achieved taking from RnD to market more than 200 products/therapies and has pioneered the evolution of therapies from chemical synthesis, biologics to cell and gene therapy. Jose is an early adopter and champion of real time predictive statistical modeling and deep machine learning.
Website: https://www.cytoimmune.com
Social Media Links: Linkedin: https://www.linkedin.com/company/cytoimmune-therapeutics Twitter: @CytoImmune
People also listened to this: A Breakthrough Solution for Treating Central Nervous System Disorders Including Strokes and Cluster Headaches
Saturday Aug 12, 2023
Saturday Aug 12, 2023
Sandesh Seth, CEO of Actinium Pharmaceuticals which is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Sandesh Seth discuss the following:
What is unique about Actinium’s radiotherapy approach?
Tell me about Iomab-B, its target population, and how it will affect the patient journey.
Actimab-A is also in AML. How is it different from Iomab-B and what’s the approach here?
What’s next in your pipeline?
Tell me what upcoming catalysts I should expect in the second half of 2023.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and several internal programs in solid tumors. Actinium holds more than 200 patents and patent applications.
Website: https://www.actiniumpharma.com
Social Media Links: Linkedin: https://linkedin.com/company/actinium-pharmaceuticals-inc-Facebook: https://facebook.com/people/Actinium-Pharmaceuticals-IncTwitter: https://twitter.com/ActiniumPharma
People also listened to this: The Miracle of Enzymes to Heal Digestive Problems
Tuesday May 23, 2023
Tuesday May 23, 2023
Randy Milby, the Chief Executive Officer and Chairman of Hillstream BioPharma, a biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death, and immuno-oncology targeted novel biologics joins eHealth Radio and the Cancer Information & Health News Channels.
Listen to interview with host Eric Michaels and guest Randy Milby discuss the following:
Please tell us a bit about your background and Hillstream BioPharma.
What developments are currently in Hillstream’s pipeline?
How does ferroptosis-targeted therapy differentiate from other cancer treatments currently available or under development?
Why is it important to Hillstream to develop drug resistant therapeutics for cancers with few treatment options?
What advice can you share with industry peers, key opinion leaders, or anyone pursuing R&D in the biotechnology space?
Looking ahead, what exciting advances do you think are on the horizon for Hillstream?
Mr. Milby previously served as Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. He is a seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets. He oversaw efforts to gain CE Market approval of Neutrolin® in the European Union and held increasing roles of responsibility at Goldman Sachs and Dupont Merck prior in his career.
Website: https://hillstreambio.com
Social Media Links: Facebook: https://facebook.com/HillstreamBioPharma Linkedin: https://linkedin.com/company/hillstream-biopharma Twitter: https://twitter.com/HillstreamB
People also listened to this: Checkable Medical: Revolutionizing Home Healthcare and Telemedicine
Tuesday Jan 31, 2023
Tuesday Jan 31, 2023
Dr. Katrina Cox, the best selling author of "The Opportunity In Cancer: How to Radically Transform Your Cancer Recovery Journey", an international bestseller in four countries across multiple categories joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. Katrina Cox discuss the following:
How does one boost their energy after cancer?
How does someone deal with anxiety and fear after cancer treatment?
Do share if you would how can one create a plan to reduce the chances of cancer recurrence?
How can one become a strong support for a cancer survivor?
Looking at the positive angle on all this - how can someone who has cancer, or has had cancer explore what the opportunity in cancer is when it’s the 2nd leading cause of death globally?
Dr. Katrina Cox is a Naturopathic Doctor, a lover of science, nature, and the human body. As a passionate healthcare practitioner, she’s spent the last decade observing, researching, and connecting with cancer survivors. Witnessing the inspirational journeys of her parents, and patients has allowed her to see the opportunity that cancer presents to each of us. As the author of the international best selling book - The Opportunity in Cancer she hopes to bring awareness and a new framework to explore solutions to the many challenges that cancer survivors and their families face. Ultimately, her goal is to help survivors begin their recovery journey on their own terms, at their own speed and in the comfort of their own homes.
Website: https://theopportunityincancer.com
Social Media Links: Facebook: https://facebook.com/CancerRemissionMission Instagram: https://instagram.com/thecancerremissionmission
People also listened to this: Charlie’s Table Gluten Free Pasta Invites Everyone to Eat Together
Thursday Sep 15, 2022
Thursday Sep 15, 2022
Dr. John E. Sylvester, Radiation Oncologist at GenesisCare, a premier provider in cancer and urology care joins eHealth Radio and the Cancer Information and Health News Channels. With over 300 expert physicians across the U.S., GenesisCare offers advanced technologies and treatments as well as personalized integrated approach to care.
Listen to interview with host Eric Michaels and guest Dr. John E. Sylvester discuss the following:
Considering the staggering statistic that 1 in 8 men will be diagnosed with prostate cancer in their lifetime, is there anything the average person can do proactively to identify prostate cancer and when should they come in for a consultation? Are there any key indicators or high-risk factors people need to know?
What are the biggest challenges people face once diagnosed with prostate cancer, and how can they overcome them?
What do you all do differently at GenesisCare, and what are the benefits for patients? What can other cancer care facilities learn from you?
What are the latest innovations in prostate cancer treatment, and what do you see coming on the horizon that could help people achieve more positive outcomes?
What is most rewarding about the work that you do?
Summary: In 2020, more than 10 million cancer screenings were missed due to the pandemic. The American Association for Cancer Research revealed between March and December 2020, the nation saw an 11 percent increase in patients diagnosed with inoperable or metastatic cancer compared to the same period in 2019.
Dr. John Sylvester has performed over 6,000 prostate brachytherapy procedures. He has developed multiple technical improvements in the procedure, by improving visualization of the urethra during the procedure, optimally utilizing R.A.P.I.D. strand, and co-developed THINStrand. He has published numerous articles and medical textbook chapters on prostate brachytherapy and co-authored and edited The Prostate Cancer Treatment Book. He wrote the white paper on 4-D Calypso image guided IMRT and was the first physician in the US to use SpaceOAR in prostate cancer IG-IMRT. Dr. Sylvester earned the “Innovation Research Award 2014” from the Manatee County Chamber of Commerce and was awarded Sarasota Magazine’s Top Doctors distinction from 2012-2016. He publishes Prostate cancer research papers every year and regularly lectures at the National Radiation Oncology Society Medical Conferences (ASTRO, ABS).
Website: https://www.genesiscare.com
Social Media Links: Facebook: https://facebook.com/GenesisCareUS Linkedin: https://linkedin.com/company/genesiscare Twitter: https://twitter.com/GenesisCareUS
Tuesday Sep 13, 2022
Tuesday Sep 13, 2022
Amelia O'Relly, Founder of How To Breast Cancer, a site and community that guides those that have received a breast cancer diagnosis and their families and friends with guidance, support, and information joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Amelia O'Relly discuss the following:
You've had a distinguished career as a Human Resources Executive with companies including Coca Cola and Home Depot. Now you have transitioned to a champion for improving the patient experience. Tell us a bit about why you founded How To Breast Cancer.
It is scary to receive a cancer diagnosis. What do you wish you knew, and what tools does How To Breast Cancer offer? Is it free? What has been the feedback?
In your opinion, why have issues related to the patient experience been lagging compared to information on treatment, prevention, and other areas? How are you helping to change this? What has been the response from the medical community -- do you have a positive story to share?
You have a gala event coming up on October 8th. Tell us about it and the goals it will achieve.
What's the biggest take away you want people to have when they discover How To Breast Cancer?
Summary: When navigating a breast cancer, or any cancer, diagnosis it can be hard to know what to do next. Where do you go from here? Who do you listen to? What do you do with all the worries, fears and questions swirling around in your head? How to Breast Cancer is your how and your guide. It's information from Amelia O'Relly, and others, that share their experience to create change.
Amelia O'Relly is the Founder of How to Breast Cancer, an organization fully dedicated to helping breast cancer patients, their loved ones, caregivers, and community by serving as a central source and a single place for helpful, easy to use tools and practices for successfully navigating the breast cancer journey. Amelia’s inspiration to create and lead how to Breast cancer began after receiving her own breast cancer diagnosis in 2019 and beginning her cancer journey…a journey that is still ongoing. Over the past two years, she’s learned that while much information exists about breast cancer, much more needs to be done to have that information available in a centralized place that is user friendly and speaks from those who know and live it day to day. A resource created through personal knowledge, experience, and empathy.
Prior to founding How to Breast Cancer, Amelia spent the last 20 years serving in executive roles with a focus on Human Resources for several fortune 500 companies, spanning multiple industries and countries. She was born in Havana, Cuba, and immigrated to the U.S. with her parents and sister in 1980. Amelia grew up in the Tampa, FL, area and earned her bachelor’s degree with honors from the University of South Florida.
Amelia now spends her time focused on creating the very best tools and resources to help others successfully navigate their breast cancer journey and is the author of the upcoming book, The Breast Cancer Guide.
Website: https://www.thebreastcancerguide.com
Social Media Links: Facebook: https://facebook.com/howtoBreastcancer Linkedin: https://linkedin.com/company/how-to-breast-cancer Instagram: https://instagram.com/howtobreastcancer Twitter: https://twitter.com/H2BreastCancer
Saturday Sep 18, 2021
Saturday Sep 18, 2021
Melanie Hardy, the Director of Genetic Counseling Services for the JScreen program joins eHealth Radio and the Health News Channel.
JScreen is a not-for-profit home education and carrier screening based out of Emory University that offers affordable at-home testing for individuals and families of Jewish descent who want to empower themselves with science-based knowledge to discover if they or their future children are at risk for Jewish genetic diseases such as Tay-Sachs, Cystic Fibrosis, or if they are at a higher risk of cancer. Unlike other screening programs, Jscreen, allows you to screen from the comfort of your own home.
Listen to interview with host Eric Michaels and guest Melanie Hardy discuss the following:
What is JScreen exactly? How did the service come to be called JScreen?
How did it start – tell us about the couple that came to you in Atlanta and their story about their child and the inspiration behind JsScreen?
How does it work for people who want to get Screened?
Who helps you understand the results – is there a doctor or Genetic Counselor who talks to you about the screening?
How long from when you order the tests until you receive results?
How many tests can you get at one time and what are costs?
I understand you just launched the CAncerGen service – tell us about this?
Talk to us more about ReproGen, is that all or is there other types of screenings?
Melanie Hardy is the Director of Genetic Counseling Services for the JScreen program. She graduated with a Bachelor’s degree in Biology from Michigan State University in 1998 and followed with a 9-year career as a high school biology, chemistry and forensics teacher. She received a Master’s degree in Biology from Georgia Southern University in 2009 and a Master’s degree in Genetic Counseling from the University of North Carolina at Greensboro in 2011. She was certified by the American Board of Genetic Counseling in 2012.
Before joining the JScreen team, Melanie worked as a prenatal genetic counselor in a Maternal Fetal Medicine specialty clinic in Richmond, VA. Her professional interests include community outreach and education, mentorship, provision of telehealth, and enhancement of the healthcare experience. In 2014, she was awarded the New Leader Award, and in 2019, she was awarded the Outstanding Volunteer Leadership Award, both by the National Society of Genetic Counselors, for involvement in a wide array of professional activities.
Website: www.jscreen.org
Social Media Links: Facebook: facebook.com/MyJScreen Instagram: @GetJScreened Twitter: @MyJScreen
Thursday Jul 15, 2021
Thursday Jul 15, 2021
Dr. Marc Hedrick, President and CEO at Plus Therapeutics which is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. Marc Hedrick discuss the following:
What is Plus Therapeutics, and what is its mission?
Tell us about your background and what brought you to Plus Therapeutics?
What is Rhenium NanoLiposome (RNL™) and how is it delivered to cancerous brain tumors?
How could RNL help advance current treatment options for GBM and why is this important for patients?
Do you think most people understand radiation and its potential benefits as a cancer therapy?
What do you think is the most common misconception that people hold about radiation as a cancer treatment?
What’s next Plus Therapeutics? Is Plus developing other investigational candidates as part of its broader pipeline?
Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
Website: plustherapeutics.com
Social Media Links: Facebook: facebook.com/plustherapeutics Instagram: instagram.com/plustherapeutics Twitter: twitter.com/plustxinc Linkedin: linkedin.com/company/plustherapeutics
Tuesday Dec 08, 2020
Tuesday Dec 08, 2020
Rodney Varner, the CEO of Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes joins eHealth Radio and the Cancer Information Diabetes and Health News Channels.
Listen to interview with host Eric Michaels and guest Rodney Varner discuss the following:
What inspires you at Genprex?
Please give us an overview of Genprex’s gene therapies in development. What is it intended to treat, and how does it work?
Could you talk more specifically about Genprex’s lead product candidate GPX-001?
Could you please give us some insight about GPX-002, gene therapy for people with diabetes and what is it comprised of?
What are the benefits of Genprex’s targeted therapies for people with non-small cell lung cancer?
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
Website: genprex.com
Social Media Links: Facebook: facebook.com/genprexinc Linkedin: linkedin.com/company/genprex Twitter: twitter.com/genprex
Saturday Dec 05, 2020
Saturday Dec 05, 2020
Myron Holubiak, President and CEO of Citius Pharmaceuticals, and Leonard Mazur, Chairman of the Board at Citius Pharmaceuticals, a specialty late-stage pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives and cancer care joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guests Myron Holubiak & Leonard Mazur discuss the following:
Please give us an overview of catheter-related bloodstream infections (CRBSIs) and central venous catheters (CVCs).
Who is at Risk for Catheter-Related Bloodstream Infections (CRBSIs)?
Please give us a brief description of Minolok and how does it help the standard of care in the management of CRBSIs?
Give us a brief description of our NoveCite subsidiary and the impact of Covid 19 patients w ARDS. What is your technology and why is it different?
How is the development of MinoWrap for mastectomies progressing after your collaboration w MD Andersen?
Why did the both of you invest 26.5 million into the company?
Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC (“Akrimax”), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008, and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur also co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC (“Triax”), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder, and, from 1995 to 2005, Chief Executive Officer, of Genesis Pharmaceuticals, Inc. (“Genesis”), a dermatological products company that marketed its products through dermatologists’ offices, and co-promoted products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company.
Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation, as Executive Vice President, ICN Pharmaceuticals, Inc., as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.
Mr. Mazur is a member of the Board of Trustees of Manor College, and is a recipient of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from Temple University, and has served in the US Marine Corps Reserves.
Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was co-founder, director and CEO of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. Mr. Holubiak was the President of Roche Laboratories, Inc. (“Roche”), a major research-based pharmaceutical company, from December 1998 to August 2001.
Prior to that, he held sales and marketing positions at Roche during his 19-year tenure there. As President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company. He was also founder of Emron, Inc., a health economics and managed care consulting company, and helped to create the Academy of Managed Care Pharmacy (AMCP). Mr. Holubiak was also a director of Bioscrip, Inc., a national home infusion company, from 2002 through 2016, and served as its Chairman of the Board from 2012 through 2016.
Since July 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. (“Assembly”) and its predecessor, Ventrus Biosciences, Inc. Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation. He received a BS in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London, as well as advanced training in health economics from the University of York’s Centre for Health Economics.
Website: citiuspharma.com